Guest Post: Colorcon

August 6, 2016

Guest Post: Colorcon

Colorcon Coatings – Achieving the Perfect Finish

If an uncoated tablet is therapeutically effective, why bother film coating? It’s an added step in production and often considered to be a specialized process requiring significant formulation and regulatory knowledge.
So why is it that the largest percentage of today’s top selling solid oral dosage forms are film coated? There are sound quality and regulatory reasons.

A Positive Contribution to Product Quality

Film coatings protect solid dosage forms and add a superior and glossy product finish with color that provides differentiation and excellent brand quality. In packaging, film coated tablets reduce waste, enhance slip in production, help avoid cross contamination, and protect cores from environmental factors.

Meeting Regulatory Expectations

Today, regulatory agencies are focusing on guidance to help reduce medication errors and improve patient adherence. New FDA Guidance Documents (April 2016) call on Innovator, Generic, and OTC manufacturers to take steps to differentiate their oral dosage forms visually and to consider using film coatings to aid the patient in swallowing tablets. (1,2)
Many companies have opportunistically seized onto these newer expectations by including a carefully selected film coating for use on their product. Some manufacturers are now applying film coatings to previously uncoated tablets using fully formulated systems. They find that working with a reliable excipient supplier such as Colorcon helps them sort through the regulatory process. (3) Innovative manufacturers around the world are converting marketed product coatings to more efficient systems. This change provides not just a great tablet finish but reaps the rewards of manufacturing efficiencies.

First Time Right with Ready Formulated Film Coating Systems

When it comes to selecting the right film coating, one name is synonymous with first-in-class quality, complete with services that continue to set global standards. That brand is Opadry®, a complete film coating system from Colorcon.
The Opadry system is not a one-size fits all product, as our customers‘ products are diverse. The name itself stands for a family of customizable solutions where we carefully match the ingredients to the customers’ color requirements, equipment capabilities, the tablet core, and their processing needs. As a fully formulated system, each Opadry is delivered ready-to-use, taking the confusion out of pigment and other ingredient choice complexity.

Fully Formulated Opadry Systems Help Lower Total Costs

Through the years, a variety of Opadry systems have been introduced that address the needs for film coating in the first place. For immediate release applications, these include the use of color for branding and differentiation, aesthetics, taste-masking, along with light, environmental and moisture protection.
All Opadry systems are high-efficiency products that contain a unique blend of polymer, plasticizer, and pigments needed to achieve the best result. Delivered as a ready-to-use dry powder, every Opadry offers the advantage of getting a product containing the right amount of excipients and pigments to ensure batch-to-batch consistency, time after time. As a complete package, a fully formulated Opadry reduces inventory management and Colorcon provides short lead times.

Opadry Means Innovation

The original Opadry brand has grown beyond the basic immediate release coating incorporating advanced polymers and novel pigments that:

  • Reduce production time; Opadry II, Opadry QX
  • Protect the core from environmental moisture; Opadry amb II
  • Provide a unique high-gloss pearl finish; Opadry fx

Materials You Can Trust

All Opadry systems are developed using high-quality materials designed to meet global compendia requirements. Due to the complexity of pharmaceutical regulations worldwide, Colorcon applies its years of formulation expertise to deliver a system for the local market to meet the customer’s specific goal. All ingredients used in Opadry products come from accredited sources supported through a global business continuity program. The result, no supply chain interruptions are experienced by the user. Regulatory filing information packages are also available from Colorcon, making the customer’s application process that much easier.

Colorcon, from Core to Coating, Your Supplier of Choice

At Colorcon, we formulate, we innovate — and we focus our coatings and excipients exclusively for pharmaceutical and nutritional oral solid dosages.
That’s why, when you set out to select the right coating or excipient for your formulation, be sure to partner with the leading company that brings you innovative products plus specialized technical support when and where you need it. Be confident with your choice.

References:

  1. FDA Guidance for Industry, Safety Considerations for Product Design to Minimuze Medication Errors,
    (April 2016). http://1.usa.gov/1SMyvSN
  2. FDA Guidance for Industry, Size Shape and Other Physical Attributes of Tablets and Capsules (June 2015).
    https://www.federalregister.gov/articles/
    2015/06/19/2015-15076/size-shape-and-other-physical-attributes-of-generic-tablets-and-capsules-guid
    ance-for-industry
  3. C. Miller, Beyond Keeping Up Appearances”The Medicine Maker (April 2016) pg. 44– Coat of Regulations

For more information contact:
Tim Horwood,
Colorcon
thorwood@colorcon.com

You can also visit the following website:
www.colorcon.com

Author: Tim Horwood, Colorcon

Read More

Vitex to Expand Into the Aerotropolis
Read More >
Vitex CEO Dr Aniss Chami Appointed Board Director of CHP Australia
Read More >
Vitex Pharmaceuticals’ Chief Executive Officer, Dr Aniss Chami, a panel discussion with Blacktown City Council.
Vitex CEO Dr Aniss Chami Joins A Panel Discussion with Blacktown City Council
Read More >
Vitex Pharmaceuticals’ Chief Procurement Officer, Lucie Chami, discusses the impact of Coronavirus on procurement via Podcast on Chartered Institute of Procurement and Supply
Vitex CPO Lucie Chami Discusses the Impact of Coronavirus
Read More >
Vitex Pharmaceuticals’ CEO, Dr Aniss Chami shared the Vitex journey at the Advanced Manufacturing Symposium hosted by Blacktown City Council, on Thursday 24 October 2019 at Sydney Motorsport Park, Eastern Creek.
Vitex CEO Dr Aniss Chami Shares the Vitex Journey at the Advanced Manufacturing Symposium
Read More >
Vitex Pharmaceuticals’ CEO, Dr Aniss Chami delivered the keynote speech at the 16th edition of the World Forum for Foreign Direct Investment (FDI) 2019 held on Wednesday 19 June 2019 in Sydney, Australia.
Vitex CEO Dr Aniss Chami Delivers Keynote Speech at the 2019 World Forum for Foreign Direct Investment
Read More >
Vitex Pharmaceuticals’ CEO, Dr Aniss Chami joined the Western City & Aerotropolis Authority Industry Symposium that took place on Monday 16 December 2019 at Warwick Farm.
Vitex CEO Dr Aniss Chami Participates at the Western City & Aerotropolis Authority Industry Symposium
Read More >
Vitex Pharmaceuticals’ CEO, Dr Aniss Chami had the pleasure of hosting over forty foreign diplomats based in NSW. The Western Sydney Investment Attraction Office, on behalf of the Department of Foreign Affairs and Trade, organised a visit to Western Sydney to showcase investment and trade opportunities in this rapidly expanding region.
Vitex CEO Dr Aniss Chami Welcomes NSW Diplomats at Vitex Pharmaceuticals
Read More >
Vitex Pharmaceuticals’ CEO, Dr Aniss Chami delivered the keynote speech at the Inaugural International Foreign Direct Investment (FDI) Summit held on Tuesday 29 October 2019 in Huzhou, China.
Vitex CEO Dr Aniss Chami Delivers Keynote Speech at the International FDI Summit in Huzhou, China
Read More >